

# Novel ERG for Detection of Hydroxychloroquine Retinopathy

NCT06035887

---

**Status** RECRUITING  
**Sponsor** King's College Hospital NHS Trust  
**Enrollment** 140 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Age ≥18 years
- HCQ groups:
  - a. HCQ use ≥5 years for patients without any high-risk factors, or ≥1 year in patients with one or more high-risk factors for HCQ retinopathy, namely: i. Dose ≥5mg/kg per day actual body weight (ABW) ii. Estimated glomerular filtration rate (eGFR) of <60mls/min/1.73m<sup>2</sup> iii. Concomitant tamoxifen use
- Control group:
- No prior HCQ exposure

### Exclusion (21)

- Cataract grade e3 of any subtype
- Recent cataract surgery within 4 weeks of recruitment
- Significant media opacity or corneal disease including, but not limited to, corneal oedema, corneal scarring, keratoconus, previous corneal transplants, severe keratoconjunctivitis sicca (requiring the use of topical serum, immunosuppressive or analogous therapy, or procedural treatment).
- Significant macular co-pathology including, but not limited to, macular degeneration, macular scarring, cystic macular oedema (for any reason), staphyloma.
- Inherited retinal and/or macular dystrophies including colour vision deficiencies
- ... and 16 more (see full listing online)

## Locations (1 total)

---

King's College Hospital, London, London, United Kingdom